A Randomized Placebo-controlled Trial of Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders (ASD)

Trial Profile

A Randomized Placebo-controlled Trial of Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders (ASD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Tideglusib (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Acronyms TIDE
  • Most Recent Events

    • 09 Feb 2016 Time frame for primary endpoint has been changed from 16 weeks to 12 weeks as reported by ClinicalTrials.gov.
    • 29 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 30 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top